At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
Mirvetuximab soravtansinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
In Brief
A Phase 2 clinical trial evaluating Mirvetuximab soravtansine for Ovarian Cancer and 2 related conditions. Completed, enrolled 79 participants across 35 sites in 7 countries.
Detailed Summary
PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
CountriesAustralia, Belgium, France, Ireland, Italy, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedSep 2021
Enrollment StartOct 2021
Primary CompletionDec 2024
TodayJul 2026
First PostedSep 13, 2021
Enrollment StartOct 19, 2021
Primary CompletionDec 12, 2024
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 4.8 years ago
Interventions
Mirvetuximab soravtansinedrug
Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle